(MENAFN- Straits Research)
Myocardial Infarction Market Size & Growth Analysis
The global myocardial infarction market size was valued at USD 2.61 billion in 2025 and is projected to grow from USD 2.82 billion in 2026 to USD 5.22 billion by 2034, registering a CAGR of 8% during the forecast period from 2026 to 2034. North America dominated the myocardial infarction market with a market share of 39.2% in 2025.
Myocardial infarction (MI) is a medical term for a heart attack. It occurs when blood supply from the coronary artery to the heart muscle gets blocked due to plaque buildup, a substance made up of cholesterol and fats. Sudden chest pain, shortness of breath, anxiety, and sweating are some of the most of common symptoms of MI. People with high blood pressure, obesity, diabetes, smoking addiction, and a family history of heart attacks are more prone to myocardial infarction. Moreover, rising incidences of coronary artery diseases and changing lifestyles are the major contributors to the growing incidence of such as diseases. Electrocardiogram, blood tests, and coronary angiogram are a few major diagnostic tests used for detection of MI.
Myocardial Infarction Market Key Takeaways
Global Market Size & Growth
2025 Market Size: USD 2.61 Billion
2026 Market Size: USD 2.82 Billion
2034 Projected Market Size: USD 5.22 Billion
Forecast Period: 2026–2034
Base Year: 2025
Market CAGR (2026–2034): 8%
Regional Insights
Largest Regional Market (2025): North America
North America Market Share (2025): 39.2%
Fastest-Growing Region: Europe
Europe CAGR (2026–2034): 7.96%
Segment Insights
By Product Type
Leading Segment: Antiplatelet agents
Market Share in 2025: 24.8%
By Distribution Channel
Fastest-growing segment: Online drug stores
CAGR: 8.34% (2026-2034)
Download a Free Sample To learn more about this report,
Myocardial Infarction Market Trends
Increasing Use of Multimodal Imaging for Myocardial Infarction Assessment
The myocardial infarction market is increasingly incorporating complementary imaging techniques to determine the underlying cause, extent, and consequences of myocardial injury. Cardiac magnetic resonance, echocardiography, coronary CT angiography, and invasive coronary imaging are being used alongside clinical assessment and biomarkers to improve characterization of myocardial infarction. This is shifting clinical practice toward more comprehensive anatomical and functional assessment rather than relying on a single diagnostic measurement.
In August 2026, the ESC, ACC, AHA, and WHF released the Fifth Universal Definition of Myocardial Infarction, incorporating cardiac and coronary imaging into the evaluation of myocardial infarction and encouraging imaging to help define its underlying aetiology.
Growing Emphasis on Personalized Secondary Prevention and Cardiac Rehabilitation
Post-myocardial-infarction care is increasingly emphasizing individualized secondary prevention and structured cardiac rehabilitation to reduce recurrent cardiovascular events and improve long-term recovery. Treatment programs are being tailored around medication adherence, exercise, lifestyle modification, risk-factor management, and patient-specific rehabilitation needs. This represents a shift in the myocardial infarction care pathway from acute hospital treatment toward longer-term management of cardiovascular risk and functional recovery.
In August 2026, the European Society of Cardiology released its first dedicated cardiac rehabilitation guidelines, reinforcing structured rehabilitation as an important component of cardiovascular recovery and long-term management.
Myocardial Infarction Market Dynamics
Market Drivers
Rising Burden of Cardiovascular Risk Factors and Coronary Disease
The myocardial infarction market is supported by the continuing burden of coronary artery disease and associated risk factors such as hypertension, diabetes, obesity, smoking, and dyslipidemia. These conditions increase the population at risk of acute coronary events and sustain demand for diagnostic testing, emergency treatment, revascularization, and secondary prevention. An aging population and increasing prevalence of multiple cardiovascular risk factors further expand the need for myocardial infarction management.
In 2026, the European Society of Cardiology continued to identify cardiovascular disease prevention and management as a major priority, with dedicated guidance addressing cardiovascular disease and chronic kidney disease and other major cardiovascular conditions.
Market Restraints
High Cost and Unequal Access to Advanced Acute Cardiac Care
Myocardial infarction treatment can require emergency hospitalization, cardiac catheterization, PCI, intensive monitoring, and long-term medication, creating substantial healthcare expenditure. Access to advanced cardiac facilities and specialist teams remains uneven across regions, particularly where emergency transport and catheterization infrastructure are limited. These differences can delay definitive treatment and restrict the adoption of advanced interventions in lower-resource healthcare systems.
In August 2026, the Fifth Universal Definition of Myocardial Infarction specifically addressed implications and adaptations for low-resource settings, highlighting the need to account for differences in diagnostic and healthcare capabilities.
Market Opportunities
Expansion of Remote Cardiac Rehabilitation and Post-Discharge Monitoring
Remote cardiac rehabilitation and digital follow-up create opportunities to extend myocardial infarction care beyond hospital-based programs. Home-based rehabilitation can combine remote monitoring, individualized exercise programs, medication support, and clinical follow-up, potentially improving participation among patients who face geographic or mobility barriers. This opportunity is focused on post-discharge care delivery rather than AI-based diagnosis or acute diagnostic technologies.
In 2026, a study published in the American Journal of Cardiology evaluated a virtual home-based cardiac rehabilitation program among patients with myocardial infarction, coronary bypass surgery, or PCI, examining its association with subsequent cardiovascular outcomes.
Market Challenges
Reducing Treatment Delays Across the Acute Care Pathway
Rapid recognition and treatment remain challenging because myocardial infarction requires coordination among emergency services, diagnostic teams, cardiologists, catheterization laboratories, and hospital systems. Delays can occur between symptom onset, emergency presentation, diagnostic confirmation, risk assessment, and revascularization. Maintaining rapid and coordinated care is particularly difficult when patients present atypically or when healthcare systems have limited specialist and interventional capacity.
In August 2026, the Fifth Universal Definition of Myocardial Infarction emphasized a standardized evaluation pathway incorporating symptoms, ECG, serial cardiac troponin measurements, and appropriate cardiac or coronary imaging to improve consistency in myocardial infarction diagnosis.
Myocardial Infarction Market Segmentation
By Product Type
Antiplatelet Agents Dominated the Market with 24.8% Share in 2025
The antiplatelet agents segment accounted for the largest share of the global myocardial infarction market at 24.8% in 2025, driven by their critical role in preventing blood clot formation, reducing recurrent cardiovascular events, and improving outcomes in patients with acute coronary syndrome.
Thrombolytics and anti-thrombotic agents continue to witness strong demand due to their effectiveness in restoring blood flow during acute myocardial infarction. β adrenergic blockers remain widely prescribed for controlling heart rate, lowering blood pressure, and reducing the risk of subsequent cardiac events. Vasodilators are commonly used to improve coronary blood flow and relieve chest pain, while angiotensin converting enzyme inhibitors and angiotensin receptor antagonists play an important role in managing blood pressure and preventing heart failure after myocardial infarction. Analgesics continue to be utilized for pain management during acute cardiac episodes, whereas glycoprotein IIb/IIIa inhibitors are increasingly used in high-risk patients undergoing percutaneous coronary interventions.
Request Customization to receive a tailored report.
By Distribution Channel
Online Drug Stores are Projected to Register the Fastest Growth at a CAGR of 8.34%
The online drug stores segment is expected to expand at the highest CAGR of 8.34% during 2026–2034, supported by increasing adoption of e-pharmacy platforms, growing digital healthcare penetration, improved home delivery services, and rising patient preference for convenient access to cardiovascular medications.
Hospitals remain the leading distribution channel due to the high volume of emergency myocardial infarction treatments and inpatient care. Hospital pharmacies continue to play a vital role in ensuring timely availability of critical medications for acute and post-operative care, while drug stores maintain steady demand by providing prescription medicines for long-term cardiac disease management and follow-up treatment.
Speak to an Analyst to discuss market opportunities.
Myocardial Infarction Market Regional Outlook
North America Myocardial Infarction Market Analysis
North America market dominated the myocardial infarction market with a 39.2% share, valued at USD 1.02 billion in 2025. The region's leadership is driven by the high prevalence of cardiovascular diseases, advanced healthcare infrastructure, increasing adoption of early diagnostic technologies, and strong availability of innovative treatment options. Rising healthcare expenditure, growing awareness of heart disease prevention, and continuous investments in cardiovascular research continue to support regional market growth.
United States Myocardial Infarction Market Insights
The US market accounted for the largest share of the North American market in 2025. Growth is driven by increasing incidence of coronary artery disease, widespread access to advanced cardiac care, rising adoption of minimally invasive treatment procedures, and strong investments in cardiovascular research and drug development. Favorable reimbursement policies and the presence of leading pharmaceutical and medical device companies further strengthen the country's market position.
Canada Myocardial Infarction Market Insights
Canada market is witnessing steady market growth due to increasing awareness of cardiovascular health, expanding access to advanced diagnostic services, rising investments in cardiac care infrastructure, and growing adoption of evidence-based treatment protocols for myocardial infarction patients.
Unlock Regional Insights to access country-level data, & regional trends.
Europe Myocardial Infarction Market Analysis
Europe market accounted for 27.4% of the global myocardial infarction market, reaching USD 0.72 billion in 2025, and is projected to register the fastest CAGR of 7.96% during the forecast period. Market growth is supported by increasing prevalence of cardiovascular disorders, expanding healthcare expenditure, growing adoption of advanced cardiac imaging technologies, and strong government initiatives promoting early diagnosis and preventive healthcare.
United Kingdom Myocardial Infarction Market Insights
The United Kingdom market represents a significant market in Europe, driven by increasing investments in cardiovascular care, expanding access to emergency cardiac treatment, growing awareness of heart disease prevention, and rising adoption of advanced diagnostic and interventional procedures.
Germany Myocardial Infarction Market Insights
Germany market leads the European market owing to its advanced healthcare infrastructure, increasing adoption of innovative cardiovascular therapies, expanding investments in cardiac research, and strong availability of specialised heart care centres and emergency medical services.
Asia Pacific Myocardial Infarction Market Analysis
Asia Pacific market accounted for 21.6% of the global myocardial infarction market, valued at USD 0.56 billion in 2025. The market is expanding due to the rising prevalence of cardiovascular diseases, growing ageing population, increasing healthcare investments, and improving access to advanced diagnostic and treatment facilities across emerging economies.
Japan Myocardial Infarction Market Insights
Japan market continues to experience steady market growth, supported by advanced healthcare infrastructure, increasing adoption of innovative cardiac treatment technologies, a rising elderly population, and growing emphasis on early diagnosis and preventive cardiovascular care.
China Myocardial Infarction Market Insights
The Chinese market accounted for the largest share of the Asia-Pacific market. Growth is supported by increasing incidence of cardiovascular diseases, expanding healthcare infrastructure, rising government investments in public healthcare, and growing adoption of advanced cardiac diagnostic and treatment solutions.
Middle East & Africa Myocardial Infarction Market Analysis
The Middle East & Africa market represented 5.0% of the global myocardial infarction market, totaling USD 0.13 billion in 2025. Rising prevalence of lifestyle-related cardiovascular diseases, improving healthcare infrastructure, increasing awareness of cardiac health, and expanding access to specialised cardiovascular care are supporting regional market growth.
UAE Myocardial Infarction Market Insights
The UAE market is a key market in the Middle East, driven by increasing investments in advanced healthcare facilities, growing adoption of modern cardiac diagnostic technologies, expanding emergency cardiovascular care services, and rising government initiatives promoting early disease detection.
Africa Myocardial Infarction Market Insights
The African market is witnessing gradual growth, supported by improving healthcare infrastructure, increasing awareness of cardiovascular diseases, expanding access to diagnostic and treatment services, and rising government and private investments in cardiac care. Countries such as South Africa, Egypt, and Kenya are creating long-term growth opportunities for market participants.
List of Key and Emerging Players in Myocardial Infarction Market
Apotex Inc.
AstraZeneca
Bayer AG
Boehringer-Ingelheim
Bristol-Myers Squibb Company
Daiichi Sankyo Co. Ltd.
Mylan N.V.
Novartis AG
Par Pharmaceutical Companies Inc.
Pfizer Inc.
Key Industry Developments
June 2026: Abbott received FDA approval for its next-generation CardioMEMSTM HERO remote monitoring reader, strengthening its cardiovascular disease management portfolio. The technology supports improved monitoring of patients with heart failure by enabling easier transmission of pulmonary artery pressure readings to healthcare providers. The advancement reflects Abbott's continued focus on connected cardiac care solutions that support patients at risk of severe cardiovascular complications, including those with previous myocardial infarction-related conditions.
May 2026: Medtronic presented new clinical data on its cardiac rhythm management technologies, including advancements in catheter-based therapies for patients with ventricular arrhythmias following myocardial infarction. The company highlighted developments involving its Affera mapping and ablation platform with Sphere-9 catheter technology, supporting research into improved treatment approaches for post-heart attack rhythm complications.
April 2026: Abbott expanded its cardiovascular innovation initiatives by advancing integrated cardiac monitoring and intervention solutions. The company continued strengthening its portfolio across structural heart, electrophysiology, and remote monitoring technologies to support earlier detection and management of cardiovascular events associated with myocardial infarction.
March 2026: Boston Scientific continued expanding its interventional cardiology portfolio through advancements in coronary intervention technologies. The company focused on improving catheter-based treatment solutions used during coronary procedures, including technologies supporting patients requiring intervention after acute coronary events.
Report Scope
Comments
No comment